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Abstract
Background: Continuous	 levodopa-	carbidopa	 intestinal	 gel	 (LCIG)	 diminishes	 daily	
“off”	 time	 and	 dyskinesia	 in	 patients	 with	 advanced	 Parkinson′s	 disease	 (PD).	
Complications are common with percutaneous endoscopic gastrostomy with a jejunal 
extension	tube	(PEG-	J).
Aim of the Study: To	report	the	clinical	outcome	of	LCIG	in	patients	with	advanced	PD	
in	the	years	2006–2014	at	Helsinki	University	Hospital.
Patients and Methods: Levodopa-	carbidopa	intestinal	gel	treatment	started	following	
PEG-	J	placement	in	patients	with	advanced	PD	after	successful	in-	hospital	LCIG	trial	
with	a	nasojejunal	 tube.	Demographics,	PEG-	J	procedures,	discontinuation	of	LCIG,	
complications and mortality were retrospectively analyzed.
Results [mean (SD)]: Sixty	patients	with	advanced	PD	[age	68(7)	years;	duration	of	PD:	
11(4)	years]	had	LCIG	treatment	for	26(23)	months.	The	majority	of	patients	with	ad-
vanced	PD	were	satisfied	with	the	LCIG	treatment.	For	51	patients	(85%),	the	pump	
was	on	for	16	hr	a	day,	and	for	nine	patients	(15%)	it	was	on	for	24	hr	a	day.	After	
6	months,	the	levodopa-	equivalent	daily	dose	(LEDD)	had	increased	by	30%	compared	
to	pre-	LCIG	LEDD.	Sixty	patients	underwent	a	total	of	156	PEG-	J	procedures,	and	48	
patients	 (80%)	 had	 a	 total	 of	 143	 complications.	 Forty-	six	 patients	 (77%)	 had	 119	
PEG-	J	or	peristomal	complications,	and	22	patients	(37%)	had	a	total	of	25	other	com-
plications.	The	most	common	complications	were	accidental	removal	of	the	J-	tube	in	
23	patients	(38%)	and	≥5%	weight	loss	in	18	patients	(30%).	Fifteen	patients	discon-
tinued	the	LCIG	after	21	(21)	months.	At	the	end	of	the	follow-	up	period	of	33(27)	
months,	38	patients	were	still	on	LCIG	and	nine	(15%)	had	died.
Conclusion: Most	patients	were	 satisfied	with	 LCIG	 treatment.	A	 few	patients	 lost	
weight	whereas	the	majority	had	complications	with	PEG-	J.	When	LCIG	treatment	is	
carried	out,	neurological	and	endoscopic	units	must	be	prepared	for	multiple	endo-
scopic procedures.
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1  | INTRODUCTION
Patients	 with	 advanced	 Parkinson’s	 disease	 (PD)	 suffer	 from	 daily	
motor fluctuations and dyskinesia. “On” time means periods of good 
motor	control	with	no	disturbing	dyskinesia,	while	 “off”	 time	 is	peri-
ods of stiffness and poor mobility. Ideal medication reduces “off” time 
and minimizes dyskinesia. Combinations of levodopa with carbidopa or 
benserazide,	dopamine	agonists,	MAO-	B	inhibitors	and	COMT	inhibi-
tors	are	the	standard	treatment	for	PD	(Horstink	et	al.,	2006).	In	the	ad-
vanced	disease	state,	wearing	off,	on-	off	phases,	or	dyskinesia	lead	to	
functional	 impairment	(Ahlskog	&	Muenter,	2001).	The	short	half-	life	
of oral levodopa and individual variation of gastric emptying in PD pa-
tients cause daily fluctuations in levodopa plasma concentration. Deep 
brain	stimulation	(DBS)	(Deep	Brain	Stimulation	for	Parkinson’s	Disease	
Study,	Group,	2001),	apomorphine	infusion	(Trenkwalder	et	al.,	2015)	
and	 continuous	 infusion	 of	 levodopa-	carbidopa	 intestinal	 gel	 (LCIG)	
(Nilsson,	Nyholm,	&	Aquilonius,	2001)	are	device-	aided	therapies	that	
can	diminish	“off”	-	time	and	dyskinesia	in	advanced	PD.	DBS,	LCIG	and	
an apomorphine pump are considered only if a combinations of the 
aforementioned	oral	drugs	is	not	sufficient.	 In	Finland	DBS	has	been	
available	since	1995,	and	LCIG	since	2006	with	100%	reimbursement.	
Apomorphine	pump	has	been	available	in	Finland	since	April	2017.
Levodopa-	carbidopa	intestinal	gel	with	a	levodopa	concentration	
of 20 mg/ml is administered via a portable pump that is connected to 
the	PEG-	J,	a	percutaneous	endoscopic	gastrostomy	(PEG)	with	a	thin-
ner	inner	J-	tube	placed	in	the	proximal	 jejunum.	LCIG	treatment	en-
sures continuous dopaminergic stimulation and it significantly reduces 
daily motor fluctuations and dyskinesia compared to oral levodopa 
(Olanow	 et	al.,	 2014).	However,	 complications	with	 the	 tube	 or	 the	
pump	are	common,	presenting	in	40%–96%	of	patients	(Devos,	2009;	
Fernandez	 et	al.,	 2013,	 2015;	 Nyholm	 et	al.,	 2008;	 Pickut,	 van	 der	
Linden,	Dethy,	Van	De	Maele,	&	de	Beyl,	2014).
The aim of the present study was to analyze the outcome of long- 
term	LCIG	treatment	in	advanced	PD,	paying	special	attention	to	com-
plications and discontinuation of the treatment in the clinical setting.
2  | PATIENTS AND METHODS
Altogether,	60	patients	with	advanced	PD	received	LCIG	therapy	at	
Helsinki	University	Hospital	between	2006	and	2014.	A	neurologist	
selected	 candidates	 for	 LCIG	 treatment	 i.e.,	 patients	 who	 reported	
substantial daily motor fluctuations and dyskinesia that could not 
be	sufficiently	controlled	with	oral	PD	medication.	Severe	dementia,	
ongoing	 psychosis,	 and	 unresponsiveness	 to	 levodopa	 were	 exclu-
sion	criteria.	The	total	daily	oral	doses	of	levodopa,	amantadine,	do-
pamine	agonists	and	MAO-	B-	and	COMT-	inhibitors	were	converted	
to	a	morning	dose	and	continuous	daily	 infusion	of	LCIG.	To	assess	
the	 response	 to	 LCIG,	 the	 patients	 were	 admitted	 to	 neurological	
ward	and	had	a	nasojejunal	tube	(Flocare	Bengmark®	10Fr,	Nutricia,	
Netherlands)	for	4–6	days	of	testing.	A	radiologist	positioned	the	tube	
near	the	 ligamentum	of	Treitz	under	fluoroscopic	control.	LCIG	was	
administered	with	a	pump	via	the	nasojejunal	tube,	and	the	response	
to	LCIG	was	assessed	with	diaries.	If	this	testing	phase	was	successful,	
the	patient	had	a	PEG-	J.
2.1 | PEG- J procedure
A	PEG-	J	tube	(Freka®	15	Fr	or	20	Fr	PEG	-	tube	and	Freka®	9	Fr	in-
testinal	Tube,	Fresenius	Kabi,	Cheshire,	UK)	was	inserted	under	endo-
scopic and fluoroscopic control by gastroenterologic surgeons in the 
endoscopic	 unit	 using	 the	 pull-	through	 method	 (Gauderer,	 Ponsky,	
&	 Izant,	 1980).	 Antibiotic	 prophylaxis	 (1.5	g	 cefuroxime,	 Zinacef®,	
GlaxoSmithKline,	Espoo,	Finland)	and	local	anesthesia	with	lidocaine	
(10	mg/ml	Lidocain®,	Orion,	Espoo,	Finland)	were	administered,	and	
conscious	sedation	was	provided	by	an	anesthesiologist.	After	place-
ment	of	the	PEG	tube,	the	inner	J	tube	was	moved	near	the	ligamen-
tum	of	Treitz	with	rat-	tooth	forceps.	If	this	failed,	a	guidewire	(Jagwire,	
Boston	Scientific,	Alajuela,	Costa	Rica)	and	a	triple	lumen	balloon	were	
passed	 to	 the	duodenum,	 the	balloon	was	 retrieved	and	 the	 J	 tube	
inserted over the guidewire. The position of the inner tube was con-
trolled	under	fluoroscopy.	The	PEG-	J	was	connected	to	a	portable	in-
fusion	pump	(CADD	legacy	1400	Duodopa	pump,	Smits	Medical	ASD,	
St	Paul,	MN,	USA).
2.2 | LCIG infusion in practice
The	LCIG	(20	mg/ml	of	levodopa	and	5	mg/ml	carbidopa;	Duodopa®,	
Abbvie)	dose	optimization	was	carried	out	 in	 the	neurologic	ward.	
All	oral	PD	medication	was	usually	stopped,	with	the	exception	of	
high- dose dopamine agonists with positive clinical response. The 
morning	 bolus	 was	 followed	 by	 a	 continuous	 infusion.	 Additional	
doses were administered by the patient when they felt they were 
entering	an	“off”	phase.	Usually,	infusion	lasted	16	hr,	supplemented	
with a sustained- release oral dose of levodopa for the night. If nec-
essary,	night	infusion	was	applied,	with	the	infusion	rate	being	about	
40%–60%	 less	 than	 infusion	 during	 the	 day.	 Control	 phone	 calls	
were	planned	 for	2–4	weeks	 after	 and	 control	 visits	 for	6	months	
after	initiation	of	LCIG	for	clinical	evaluation	in	the	outpatient	clinic.	
The patients were advised to gradually increase the daily infusion 
if several extra doses had to be taken daily. In cases of inner tube 
problems,	the	patients	were	advised	to	administer	LCIG	via	PEG	to	
the gastric space or to restart oral medication. If an infusion prob-
lem	occurred,	a	scheduled	admission	to	the	neurological	ward	was	
arranged,	with	 a	 subsequent	 endoscopic	procedure	 to	 correct	 the	
tube problem.
2.3 | Data collection at baseline and during the 
follow- up
The	following	data	were	collected:	duration	of	PD,	age	at	onset	of	
PD,	preceding	PD	medication,	ASA	(Physical	Status	Classification	of	
the	American	Society	of	Anesthesiologists)	class,	body	mass	 index	
(BMI),	concomitant	diseases,	details	of	the	PEG-	J	procedure,	 living	
conditions	(alone,	with	a	spouse,	in	institutional	care),	a	mini-	mental	
state	examination	 (with	MMSE	≥25	 indicating	normal	cognition),	a	
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Hoehn	and	Yahr	scale	assessment,	neurosurgical	contraindications	
(coagulopathy,	 cognitive	 impairment).	 Also	 daily	 hours	 on	 LCIG,	
LCIG	doses	after	6	months,	and	any	additional	oral	medication	data	
were	collected.	At	the	end	of	the	follow-	up	in	November	2015,	in-
formation about weight loss (weight change as a percentage during 
follow-	up),	living	conditions	and	discontinuation	of	the	LCIG	treat-
ment	was	gathered.	The	number	of	contacts	with	the	stoma	nurse,	
data	of	PEG-	J	 related	 (tube	occlusion,	accidental	 removal	of	 inner	
tube,	dislocation	of	the	inner	tube	backwards	into	the	stomach,	tube	
breakage),	 peristomal	 (stoma	 leakage,	 granulation	 tissue	 around	
stoma,	 skin	excoriation,	 abscess	or	 infection,	PEG	 tube	hat	buried	
in	gastric	wall,	 i.e.,	buried	bumper	syndrome	 (BBS)),	or	other	 (≥5%	
weight	 loss,	 gastric	 ulceration	 caused	 by	 inner	 tube,	 neurological)	
complications and mortality were collected from the patient files 
for	 the	study.	Underweight	was	defined	as	a	BMI	of	<18.5	m2/kg,	
normal	weight	as	a	BMI	18.5–25	m2/kg,	and	overweight	as	a	BMI	
of	>25	m2/kg.
2.4 | Informed consent statement
The study was approved by the hospital ethics committee. Data 
extraction occurred retrospectively from hospital medical records. 
According	to	Finnish	law,	retrospective	research	using	hospital	medi-
cal	files	does	not	require	informed	consent	from	the	study	subjects.
2.5 | Statistics
The results are reported as means and standard deviation (SD).	The	
significance of differences in categorical data was determined using 
Fisher’s	exact	test.	The	Mann–Whitney	U test was used to discover 
the	 differences	 in	 continuous	 variables.	 A	 level	 of	 p < .05	 was	 re-
garded	 as	 statistically	 significant,	 and	 two	 tailed	 tests	 were	 used.	
Statistical	calculations	were	generated	using	 IBM	SPSS	Statistics	21	
(International	Business	Machines	Corporation,	Endicott,	NY,	USA).
3  | RESULTS
Mean	age	at	onset	of	PD	was	56	 (8)	years,	and	 the	duration	of	PD	
was	11	 (4)	years	before	LCIG	treatment.	There	were	32	men	 (53%)	
and	28	women	(47%)	with	a	mean	age	of	68	(7)	years,	and	27	partici-
pants	(45%)	were	70	or	older.	Baseline	characteristics	are	presented	
in	Table	1.	The	mean	Hoehn	and	Yahr	 score	 in	 the	 “on”	phase	was	
2.7	(0.7).	At	the	onset	of	LCIG	treatment,	all	the	patients	had	been	on	
levodopa	only,	or	a	combination	of	amantadine,	a	dopamine	agonist,	
and	MAO-	B-	or	COMT-	inhibitors,	with	a	mean	levodopa-	equivalent	
daily	dose	 (LEDD)	of	1,266	 (441)	mg.	Ten	patients	 (17%)	were	 tak-
ing	only	levodopa,	18	(31%)	were	taking	two	drugs	and	30	(52%)	had	
three	 or	more	 different	 drugs	 daily.	 An	MMSE	 test	was	 performed	
on	48	patients	prior	to	LCIG	treatment.	The	mean	MMSE	score	was	
26	 (3).	Altogether,	 29	patients	 refused	or	 had	 contraindications	 for	
DBS	treatment.	The	details	of	the	PEG-	J	procedure	are	presented	in	
Table 2.
3.1 | LCIG dose
After	discharge,	51	patients	(85%)	had	daily	LCIG	infusion,	and	nine	
cases	(15%)	were	24	hr	a	day.	The	mean	daily	LCIG	dose	was	1,651	
(595)	mg.	At	6	months,	42	patients	 (78%)	had	daily	 infusion	and	12	
(22%)	had	24-	hr	infusion.	In	most	cases	(44),	the	LEDD	had	increased	
by	 505	 (304)	mg	 compared	with	 the	 baseline.	 In	 nine	 patients,	 the	
LEDD	had	decreased	by	255	(126)	mg.	Doses	of	LCIG	at	baseline	and	
6	months	were:	morning	bolus	191	(67)	mg	vs.	170	(71)	mg,	continu-
ous	infusion	73	(27)	mg/hr	vs.	81	(29)	mg/hr	(6	a.m.–10	p.m.)	and	57	
(26)	mg/hr	vs.	72	(43)	mg/hr	(10	p.m.–6	a.m.),	correspondingly.
At	the	end	of	the	follow-	up	period	of	33	(24)	months,	38	patients	
(63%)	were	on	LCIG,	7	(12%)	had	been	on	LCIG	until	death,	13	(22%)	
had	discontinued	LCIG	and	were	alive,	and	two	patients	(3%)	discon-
tinued	LCIG	and	died	later.
TABLE  1 Baseline	characteristics	of	PD	patients	on	LCIG	
treatment
Demographics n = 60
ASA	I 0
ASA	II 3	(5%)
ASA	III 51	(85%)
ASA	IV 6	(10%)
Coronary/- heart disease 17	(28%)
Diabetes 8	(13%)
Psychiatric diagnosis 11	(18%)
MMSE	≤24 11	(23%)
Hoehn	and	Yahr	score	on	phase	≥4 6	(10%)
Lives	with	a	spouse 44	(73%)
Lives	alone 12	(20%)
In sheltered housing with assistance 4	(7%)
Walker as mobility aid 15	(25%)
Wheelchair or crutches as mobility aid 6	(11%)
PD,	 Parkinson’s	 disease;	 LCIG,	 levodopa-	carbidopa	 intestinal	 gel;	 ASA,	
data	 of	 physical	 status	 classification	 of	 the	 American	 Society	 of	
Anesthesiologists	ASA	class;	MMSE,	mini-	mental	state	examination.
TABLE  2 PEG-	J	placement	procedure	in	60	patients
Time	from	nasojejunal	test	tube	placement	to	PEG-	J	
placement; days; mean (SD)
6.5	(2.7)
Total	hospital	stay,	days;	mean	(SD) 11	(4)
Hospital	stay	after	PEG-	J	placement,	days 3.9	(3.9)
Length	of	the	procedure,	min;	mean	(SD) 31	(16)
Antibiotic	prophylaxis 48	(87%)
PEG-	J:	Fresenius	Freka®	15	Fr 51	(85%)
PEG-	J:	Boston® 20 Fr 9	(15%)
Inner tube in the descending or transverse duodenum 6	(10%)
Inner tube in the ligament of Treitz 54	(90%)
PEG-	J,	percutaneous	endoscopic	gastrostomy	with	jejunal	tube;	SD,	stand-
ard deviation.
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Thirty-	two	patients	were	on	LCIG	for	more	than	2	years,	and	12	
patients	 for	 more	 than	 4	years.	 Fifty-	three	 patients	 (90%)	 felt	 that	
LCIG	 treatment	 still	 substantially	 alleviated	motor	 symptoms,	when	
questioned	at	6	months	and	beyond.
3.2 | Changes in weight, living conditions and need 
for walking devices during LCIG treatment
At	baseline,	the	mean	BMI	of	the	patients	was	24.7	(4.2)	kg/m2: only 
three	patients	(5%)	were	underweight,	31	(57%)	were	normal	weight	
and	 26	 (43%)	were	 overweight.	 At	 the	 end	 of	 the	 follow-	up,	 eight	
patients	(13%)	were	underweight,	31	(52%)	were	normal	weight	and	
21	(35%)	were	overweight.	The	weight	change	as	a	percentage	was	
−3.3%	 (10.7%)	 in	 25.7	 (23.1)	 months.	 Eighteen	 patients	 (30%)	 had	
weight	loss	of	≥5%,	and	in	12	patients	(20%),	weight	loss	was	≥10%.	
One	 patient	 had	 fatal	 weight	 loss	 despite	 discontinuation	 of	 LCIG.	
Body	CT	did	not	show	any	malignancy.	The	autopsy	failed	to	reveal	
any clear cause for his deterioration. Two patients had peripheral neu-
ropathy	prior	to	LCIG,	probably	due	to	diabetes	and	spinal	stenosis.
At	the	end	of	the	follow-	up,	38	patients	(66%)	were	still	living	at	
home	with	their	spouse	or	alone,	17	(29%)	were	in	institutional	care,	
(mainly	 sheltered	housing	with	24-	hr	assistance),	 and	 three	patients	
had intervals at home and in institutions. Nine patients originally liv-
ing	with	their	spouse	(21%)	and	four	originally	living	alone	(33%)	had	
moved to sheltered housing. The need to use a walker increased by 
40%,	 (n	=	21,	 37%)	 and	 a	wheelchair	 by	50%	 (n	=	6;	 11%),	 and	 two	
patients became bedridden.
3.3 | Discontinuation
Cognitive decline or dementia at the baseline or appearance of these 
symptoms during follow up were the most common causes of infu-
sion	 withdrawal,	 occurring	 in	 seven	 patients	 after	 27	 (25)	 months	
of	 LCIG.	 In	 two	 bedridden	 patients	 living	 in	 institutions,	 LCIG	was	
stopped	after	38	(12)	months.	One	patient	was	suffering	from	stoma	
problems	and	discontinued	the	treatment	at	19	months.	Two	patients	
(3.3%)	stopped	LCIG	after	3	months	and	5	months	because	of	 inef-
ficacy.	One	patient	subjectively	felt	dizziness	during	LCIG	treatment	
and	decided	to	discontinue	the	LCIG	infusion	after	a	month,	although	
clinical examination showed no signs of either postural instability or 
orthostatic	hypotension.	Altogether,	after	a	mean	of	21	(21)	months,	
LCIG	was	discontinued	in	15	patients,	and	in	11	cases	the	reason	was	
recurrent removal of the inner tube by the patient.
3.4 | Complications
Sixty	patients	underwent	a	 total	of	156	endoscopic	procedures.	An	
additional	96	endoscopic	procedures	following	60	PEG-	J	placements	
are	presented	in	Table	3,	and	complications	related	to	LCIG	treatment	
are	shown	in	Table	4.	There	were	48	patients	(80%)	with	a	total	of	143	
complications,	and	only	12	patients	with	no	complications.	Altogether,	
46	patients	 (77%)	had	a	total	of	119	PEG-	J	or	peristomal	complica-
tions,	and	22	(37%)	had	a	total	of	25	other	complications.	On	average,	
patients	had	2.4	 (2.1)	 complications.	 In	30	days	after	PEG-	J,	11	pa-
tients	 (18%)	had	complication	 (six	peristomal	 infections,	one	granu-
lation,	 one	 gastric	 hematoma,	 one	 nonspecific	 infection,	 one	 knot	
and	occlusion,	 and	one	disorientation). Thirty- one patients visited a 
stoma	nurse	a	total	of	121	times.	Accidental	removal	of	the	inner	tube	
TABLE  3 Additional	procedures	after	PEG-	J	placement	in	the	
endoscopy unit (n	=	96)
Hospital	stay,	days;	mean(SD) 2.3	(3.7)
Length	of	the	procedure,	min;	mean	(SD) 19	(11)
Indications for the procedure
Accidental	removal	of	inner	tube 37	(38%)
Tube occlusion 27	(29%)
Tube break 14	(15%)
Stoma leak 4	(4%)
Dislocation of the inner tube backwards into the 
stomach
2	(2%)
Thicker	PEG-	J	for	nutrition 4	(4%)
Discontinuation of the treatment 8	(8%)
Procedures: n	=	96
Inner tube placement or exchange 45	(47%)
PEG-	J	tube	exchange 25	(26%)
Testing	the	tube,	checking	with	fluoroscopy	or	
gastroscopy,	exchanging	the	caps
13	(14%)
Removal	of	the	PEG-	J	systema 13	(14%)
PEG-	J,	 percutaneous	endoscopic	 gastrostomy-	jejunal	 tube;	SD,	 standard	
deviation.
aOf	15	patients	discontinuing	LCIG,	two	patients	used	the	PEG	for	nutri-
tion and it was not removed.
TABLE  4 Complications	in	60	patients	on	LCIG
Complication n = 60
Peristomal complications:
Buried	PEG	bumper 1	(1%)
Skin	problems,	leaking	stoma 12	(20%)
Nonspecific infection 4	(7%)
Skin	infection,	abscess 5	(8%)
Granulation	tissue 21	(35%)
Tube complications:
Tube occlusion 13	(22%)
Accidental	removal	of	inner	tube 23	(38%)
Dislocation of the inner tube backwards into the 
stomach
5	(8%)
Tube break 11	(18%)
Other complications:
Weight	loss	≥5% 18	(30%)
Neurologic symptoms 3	(5%)
Pump issue 3	(5%)
Peritonitis 0
LCIG,	levodopa-	carbidopa	intestinal	gel.
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occurred significantly more often in patients with cognitive decline 
(MMSE	<24),	than	in	those	without	it:	8	(73%)	vs.	12	(35%);	p	=	.034.	
There were no peritonitis cases during the follow- up.
3.5 | Mortality
According	to	death	certificates	provided	by	Statistics	Finland,	there	
were	no	PEG-	J	related	complications	or	deaths.	Altogether,	nine	pa-
tients	died,	seven	of	whom	were	on	LCIG	until	death.	Two	patients	
died	 3.7	 and	 21.5	months	 after	 discontinuing	 LCIG,	 respectively.	
The	time	from	the	start	of	LCIG	to	death	was	26.6	(14)	months.	The	
causes of death were defined by clinical examination in four patients 
and by clinical autopsy in five patients. The immediate causes of 
death were pneumonia (n	=	4),	advanced	PD	(n	=	2),	coronary	heart	
disease or insufficiency (n	=	2)	and	pulmonary	embolism	(n	=	1).	The	
underlying causes of death were PD (n	=	7)	and	coronary	heart	dis-
ease (n	=	2).
Body	mass	index	at	onset	was	significantly	higher	in	those	alive	at	
the	end	of	the	follow-	up	compared	to	those	who	died:	25.1(4.4)	vs.	
22.2(3.4);	p	=	.043.	Similarly,	BMI	at	the	latest	follow-	up	visit	was	sig-
nificantly higher in those alive at the end of the follow- up than in those 
who	died	during	the	follow-	up,	at	24.3	 (4.0)	vs.	18.9	 (3.1);	p = .001. 
Four	underweight	patients	(44%)	died,	compared	to	five	patients	(8%)	
with normal weight or overweight; p = .013.
4  | DISCUSSION
Levodopa-	carbidopa	intestinal	gel	treatment	has	proved	to	be	effec-
tive in reducing levodopa- related dyskinesia and diminishing off time 
compared	to	oral	medication,	 leading	to	 improvement	 in	the	quality	
of	 life	 (Antonini,	 Yegin,	 Preda,	 Bergmann,	&	Poewe,	 2015;	 Lopiano	
et	al.,	2016;	Olanow	et	al.,	2014;	Wirdefeldt,	Odin,	&	Nyholm,	2016).	
We	present	data	on	LCIG	therapy,	focusing	on	complications.	The	ma-
jority of our patients were satisfied with the infusion during follow-
	up.	 There	were,	 however,	 numerous	 tube	 and	 stoma	 complications	
related	to	LCIG,	as	reported	previously	(Fernandez	et	al.,	2015;	Lang	
et	al.,	2016;	Nilsson	et	al.,	2001).
In	most	 of	 our	 patients,	 LEDD	was	 increased	 at	 6	months	 com-
pared	to	baseline.	The	LEDD	increase	may	be	caused	by	disease	pro-
gression.	We	had	12	patients	(20%)	with	their	LCIG	pump	running	for	
24	hr.	That	 is	 slightly	more	 than	previously	 reported	by	Devos	et	al.	
(10%	LCIG	for	24	hr)	(Devos,	2009).	One	study	showed	a	quite	stable	
LEDD	on	LCIG	for	12	months	(Antonini	et	al.,	2015).
In	some	studies,	dementia	was	an	exclusion	criterion,	and	only	pa-
tients	with	 an	MMSE	of	28–29	were	 included	 (Epstein	et	al.,	 2016;	
Fernandez	et	al.,	2015).	In	a	French	multicentre	study	(Devos,	2009),	
50%	of	the	patients	on	LCIG	had	cognitive	disorders	suggestive	of	PD	
dementia.	We	 found	 LCIG	 suitable	 for	 patients	with	mild	 dementia	
living	with	a	motivated	spouse.	However,	there	was	more	accidental	
tube	removal	in	patients	with	cognitive	decline.	Hence,	patients	with	
dementia	living	alone	appear	not	to	be	suitable	candidates	for	LCIG.	
Despite	the	LCIG	treatment,	29%	of	our	patients	were	in	institutional	
care,	mainly	sheltered	housing	with	24-	hr	assistance	at	the	end	of	the	
follow- up.
Several technical problems and complications increase the annual 
admission	 rate	 and	 contact	with	 the	 hospital	 (Nyholm	 et	al.,	 2008).	
Complications	with	 the	 PEG-	J	 tube	 (Devos,	 2009;	 Fernandez	 et	al.,	
2013;	Nyholm	et	al.,	2008)	are	similar	to	complications	related	to	PEG	
for	 feeding	 purposes	 (Schapiro	 &	 Edmundowicz,	 1996;	 Udd	 et	al.,	
2015).	The	risk	of	peritonitis	has	varied	between	zero	and	4%	(Devos,	
2009;	Epstein	 et	al.,	 2016;	 Lang	et	al.,	 2016;	Palhagen	et	al.,	 2016),	
and	 other	 serious	 complications	 like	 colonic	 perforations,	 gastrop-
leural	 fistula	 (Klostermann	et	al.,	2012)	and	 liver	 injury	 (Pickut	et	al.,	
2014),	 have	 also	 been	 described.	 In	 our	 material,	 we	 did	 not	 have	
any	peritonitis,	 nor	 any	need	 for	 emergency	 abdominal	 surgery	due	
to	LCIG	complications.	A	peristomal	infection	risk	of	8%	is	compara-
ble	with	the	literature:	10%–20%	(Devos,	2009;	Epstein	et	al.,	2016;	
Fernandez	et	al.,	2015;	Olanow	et	al.,	2014).	Inner	tube	complications	
were	mostly	accidental	removal,	kinking	or	dislocation	of	the	tube	oc-
curring	during	the	LCIG	treatment	in	physically	active	patients,	some-
times	 suffering	 from	 disorientation	 (Devos,	 2009;	 Fernandez	 et	al.,	
2013;	Nyholm	et	al.,	2008;	Pickut	et	al.,	2014).	We	did	not	find	any	
cases	of	inner	tube-	induced	duodenal	decubitus	ulcer	(Martino	et	al.,	
2016),	 or	 bezoar	 sometimes	 present	 in	 these	 patients.	 Our	 results	
showed	that	13	patients	had	a	total	of	27	tube	occlusions,	and	eight	
of	them	(61%)	had	altogether	ten	knots	in	the	inner	tube.	Previously,	
only three case reports of five patients with knotting of the inner tube 
had	been	published	(del-	Hoyo-	Francisco	et	al.,	2015;	Krones,	Zollner,	
&	Petritsch,	2012;	Nyholm	et	al.,	2008).	The	Freka® intestinal tube has 
an	angled,	C-	shaped	 tip,	and	 this	may	predispose	 the	 tube	 to	knots	
(Figure	1).	The	present	results	showing	that	removal	of	the	inner	tube	
occurs more often in patients with dementia are supported by previ-
ous	findings	(Devos,	2009).	Logically,	among	patients	with	no	demen-
tia,	the	rate	is	lower	(Epstein	et	al.,	2016;	Fernandez	et	al.,	2015).
The triangular external fixation plate of the Freka®	PEG-	J	 tube	 is	
suboptimal,	because	it	glides	along	the	PEG	tube,	allowing	the	PEG	to	
move back and forth. This movement may even predispose the patient 
F IGURE  1 Naive and knotted jejunal 
tube
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to peritonitis in the first days when the stoma is maturing (Epstein et 
al.,	2016).	The	skin	around	the	peristomal	area	may	become	irritated	by	
leaking	gastric	fluids.	Granulation	formation	needs	referral	to	a	stoma	
nurse.	Granulation	tissue	was	more	common	in	our	patients	(35%)	com-
pared	to	other	series	(20%–22%)	(Epstein	et	al.,	2016;	Lang	et	al.,	2016).
Weight	loss	is	an	adverse	event	increasing	the	risk	of	death,	and	is	
partly associated with the natural course of PD. One third of our pa-
tients	had	≥5%	weight	loss	during	the	follow-	up	with	one	fatal	weight	
loss	 despite	 discontinuation	 of	 LCIG.	 Decreased	 weight	 has	 been	
observed	in	5%–10%	of	LCIG	patients	(Antonini	et	al.,	2015;	Merola	
et	al.,	2016).	The	mechanism	for	weight	loss	in	LCIG	remains	ambig-
uous.	Monitoring	weight	during	LCIG	treatment	 is	essential	to	avoid	
serious weight loss.
Eighty percent of the patients had complications leading to mul-
tiple	 endoscopic	 procedures,	 but	 still	 90%	 were	 satisfied	 with	 the	
treatment. Some of the complications may therefore be related to the 
suboptimal	devices	and	tubes.	A	new	T-	port	was	found	to	be	well	tol-
erated,	and	it	had	a	low	number	of	tube	problems,	but	proper	clean-
ing	 and	 local	 treatment	 of	 the	 stoma	 site	were	 necessary	 (van	 Laar,	
Nyholm,	&	Nyman,	2016).	The	use	of	a	T-	port	 is	not	widely	 spread,	
though.
Currently,	there	are	no	guidelines	for	withdrawal	of	LCIG.	If	the	
patient	 is	 bedridden,	 disoriented	 and	 already	 needs	maximal	 care,	
LCIG	probably	may	not	 give	 any	 significant	 health	 benefit.	 Several	
removals of the inner tube by a patient during the treatment suggest 
that the mental condition of that patient has significantly deterio-
rated.	In	these	cases,	discontinuation	of	LCIG	should	be	individually	
considered.	Further,	several	replacements	of	the	inner	tube	increase	
the burden of already limited hospital resources. Continuous weight 
loss	can	even	be	a	fatal	complication,	and	therefore	needs	monitor-
ing. Close co- operation between neurological and endoscopic units 
is	 required,	and	units	must	be	prepared	 for	common	and	recurrent	
PEG-	J	problems	when	LCIG	treatment	for	advanced	PD	is	carried	out.
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